Abramovic, I.; Vrhovec, B.; Skara, L.; Vrtaric, A.; Nikolac Gabaj, N.; Kulis, T.; Stimac, G.; Ljiljak, D.; Ruzic, B.; Kastelan, Z.;
et al. MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia. Cancers 2021, 13, 2068.
https://doi.org/10.3390/cancers13092068
AMA Style
Abramovic I, Vrhovec B, Skara L, Vrtaric A, Nikolac Gabaj N, Kulis T, Stimac G, Ljiljak D, Ruzic B, Kastelan Z,
et al. MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia. Cancers. 2021; 13(9):2068.
https://doi.org/10.3390/cancers13092068
Chicago/Turabian Style
Abramovic, Irena, Borna Vrhovec, Lucija Skara, Alen Vrtaric, Nora Nikolac Gabaj, Tomislav Kulis, Goran Stimac, Dejan Ljiljak, Boris Ruzic, Zeljko Kastelan,
and et al. 2021. "MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia" Cancers 13, no. 9: 2068.
https://doi.org/10.3390/cancers13092068
APA Style
Abramovic, I., Vrhovec, B., Skara, L., Vrtaric, A., Nikolac Gabaj, N., Kulis, T., Stimac, G., Ljiljak, D., Ruzic, B., Kastelan, Z., Kruslin, B., Bulic-Jakus, F., Ulamec, M., Katusic-Bojanac, A., & Sincic, N.
(2021). MiR-182-5p and miR-375-3p Have Higher Performance Than PSA in Discriminating Prostate Cancer from Benign Prostate Hyperplasia. Cancers, 13(9), 2068.
https://doi.org/10.3390/cancers13092068
